Sandoz and Polpharma Biologics have become the first companies to get FDA approval for a biosimilar of Biogen's blockbuster multiple sclerosis therapy Tysabri, after overcoming a bid by Biogen to ...

Biogen’s hopes that one of its established multiple sclerosis drugs might also help stroke sufferers have been dashed. Natalizumab – best known as MS drug Tysabri - failed to show any benefits ...

Biogen enhances its portfolio and margins amidst market challenges and competition. Click here to find out why BIIB stock is ...

Balancing risk and benefit Biogen’s recombinant humanized monoclonal antibody, natalizumab (TYSABRI®), mediates lymphocyte and monocyte cell adhesion and transendothelial migration via the ...

With its move to MIT’s Volpe Center in Kendall Square, the drugmaker is consolidating its local footprint from three ...

Fortunately, the S&P 500 recovered to new all-time highs by August 2020 and is now up about 150% from its COVID lows.

Sales of Biogen’s key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza are declining due to competitive pressure. Biogen has ...

The multiple sclerosis drug Tysabri sales were down to $415.4 million from $464.7 million. Also Read: FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Biogen, Inc. is a biopharmaceutical company ... Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM ...